Cardiological aspects of tadalafil safety


Дәйексөз келтіру

Толық мәтін

Аннотация

Авторлар туралы

O Talibov

O Talibov

Әдебиет тізімі

  1. National Institutes of health consensus development panel on impotence. J. A. M. A. 1993; 270: 83-90.
  2. Watts G. F., Chew K. K., Stuckey B. G. The erectile-endothelial dysfunction nexus: new opportunities for cardiovascular risk prevention. Nat. Clin. Pract. Cardiovasc. Med. 2007; 4 (5): 263-273.
  3. Guay A. T. Erectile dysfunction ? endothelial dysfunction. Endocrinol. Metab. Clin. N. Am. 2007; 36: 453-463.
  4. Braun M., Wassmer G., Klotz T. et al. Epidemiology of erectile dysfunction: Results of the 'Cologne Male Survey'. Int. J. Impot. Res. 2000; 12: 305-311.
  5. Ponholzer A., Temml C., Mock K. et al. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur. Urol. 2005; 47: 80-86.
  6. Jackson G., Rosen R., Kloner R. A., Kostis J. The second Princeton consensus on sexual dysfunction and cardiac risk: New guidelines for sexual medicine. J. Sex. Med. 2006; 3: 28-36.
  7. Kloner R. A., Mitchell M., Emmick J. T. Cardiovascular effects of tadalafil. Am. J. Cardiol. 2003; 92 (9A): 37M-46M.
  8. Jackson G., Kloner R. A., Costigan T. M. et al. Update on the clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events. J. Sex. Med. 2004; 1: 157-163.
  9. Kloner R. A., Jackson G., Hutter A. M. et al. Cardiovascular safety update of tadalafil: retrospective analysis of data from placebo-controlled an open-label clinical trials of tadalafil with as needed, three times-per-week or once-a-day dosing. Am. J. Cardiol. 2006; 97: 1778-1784.
  10. Lewis R. W., Sadovsky R., Eardley I. et al. The efficacy of tadalafil in clinical populations. J. Sex. Med. 2005; 2 (4): 517-531.
  11. Vardi M., Nini A. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. Cochrane Database Syst. Rev. 2007; Issue 1.
  12. Goldstein I., Kim E., Steers W. D. et al. Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: multiple observations in men with erectile dysfunction in National Tadalafil Study in the US. J. Sex. Med. 2007; 4 (1): 166-175; (2): 522.
  13. Hazell L., Boshier A., Harris S. et al. An observational cohort study investigating the cardiovascular safety of tadalafil when prescribed in primary care in England: mortality due to ischaemic heart disease. Br. J. Urol. Int. 2007; 99 (2): 387-393.
  14. http://www.azcert.org/medical-pros/drug-lists/list-03.cfm?sort = Generic_name
  15. Data on file, Lilly Research Lboratories, Eli Lilly and Company, Indianapolis, Indiana.
  16. Emmick J. T., Stuewe S. R., Mitchell M. Overview of the cardiovascular effects of tadalafil. Eur. Heart J. 2002; 4 (suppl. H): H32-H47.
  17. Carson C. C. 3-rd. Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors. Am. J. Cardiol. 2005; 96 (12B): 37M-41M.
  18. Beasley C. M. Jr., Mitchell M. I., Dmitrienko A. A. et al. The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval. J. Am. Coll. Cardiol. 2005; 46 (4): 678-687.
  19. Rashid A. The efficacy and safety of PDE5 inhibitors. Clin. Cornerstone 2005; 7 (1): 47-56.
  20. Hickey K., Bokhari S., Shahzad A. et al. Tadalafil does not alter coronary perfusion at rest or after pharmacological stress in subjects with coronary artery disease. Eur. Heart J. 2003; 24 (abstr. suppl.): 563.
  21. Patterson D., McDonald T. M., Effron M. B. et al. Tadalafil does not affect time to ischemia during exercise stress testing in patients with coronary artery disease. Int. J. Impot. Res. 2002; 14 (suppl. 3): S102.
  22. Jackson G. Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors. Am. J. Cardiol. 2005; 96 (12B): 32M-36M.
  23. Bellotto F., Ruscazio M., Bonanni G. et al. Immediate- and late-hemodynamic coronary effects of tadalafil in men with erectile dysfunction and coronary artery disease. Int. J. Impot. Res. 2008; 20 (2): 168-172.
  24. Sesti C., Florio V., Johnson E. G., Kloner R. A. The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size. Int. J. Impot. Res. 2007; 19 (1): 55-61.
  25. Hutter A. M. Jr., Kloner R. A., Watkins V. et al. Blood pressure and cardiovascular effects of tadalafil, a new PDES inhibitor. Am. J. Hypertens. 2002; 15 (4, pt 2): 140A.
  26. Toque H. A., Teixeira C. E., Priviero F. B. et al. Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets. Br. J. Pharmacol. 2008; 154 (4): 787-796.
  27. Seftel A. D. Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. Clin. Cardiol. 2004; 27 (4, suppl. I): I14-I19.
  28. Bailey D. G., Dresser G. K. Interactions between grapefruit juice and cardiovascular drugs. Am. J. Cardiovasc. Drugs 2004; 4 (5): 281-297.
  29. Tsukamoto S., Aburatani M., Ohta T. Isolation of CYP3A4 inhibitors from the Black Cohosh (Cimicifuga racemosa) Evidence-based Compl. Alt. Med. 2005; 2 (2): 223-226.
  30. Kloner R. A., Mitchell M. I., Bedding A. et al. Pharmacodynamic interactions between tadalafil and nitrates compared to sildenafil. J. Am. Coll. Cardiol. 2002; 39 (5, suppl. A): 291A.
  31. Park J. W., Leithдuser B., Jung F. Clinical sublingual application of liquid nitrendipine does not result in critical hypotension in healthy volunteers under phosphodiesterase-5 inhibition. Hemorheol. Microcirc. 2008; 39 (1-4): 323-328.
  32. Prisant L. M. Phosphodiesterase-5 inhibitors and their hemodynamic effects. Curr. Hypertens. Rep. 2006; 8 (4): 345-351.
  33. Kloner R. A., Sadovsky R., Johnson E. G. et al. Efficacy of tadalafil in the treatment of erectile dysfunction in hypertensive men on concomitant thiazide diuretic therapy. Int. J. Impot. Res. 2005; 17 (5): 450-454.
  34. Reffelmann T., Kieback A., Kloner R. A. The cardiovascular safety of tadalafil. Expert. Opin. Drug Saf. 2008; 7 (1): 43-52.
  35. Kloner R. A., Jackson G., Emmick J. T. et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J. Urol. (Baltimore) 2004; 172 (5, pt 1): 1935-1940.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2009

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>